OpenAI has created an AI model for longevity science that focuses on engineering proteins to turn regular cells into stem cells. The company claims that its model, GPT-4b micro, has suggested ways to re-engineer protein factors to increase their function, with promising preliminary results. This project started when Retro Biosciences, a longevity research company, approached OpenAI for collaboration. The goal is to extend the human lifespan by 10 years by studying Yamanaka factors. The proteins are believed to be the key to rejuvenating animals, building human organs, and providing replacement cells. The potential for scientific discovery using AI is a major focus for OpenAI, with CEO Sam Altman expressing confidence in the companys ability to build artificial general intelligence. This venture into biological data marks a significant step towards true AI-driven discoveries in the scientific community.
